6461 logo

Intech Biopharm Corporation Stock Price

TPEX:6461 Community·NT$2.9b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

6461 Share Price Performance

NT$18.05
-2.20 (-10.86%)
NT$18.05
-2.20 (-10.86%)
Price NT$18.05

6461 Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Medium-low risk with worrying balance sheet.

6 Risks
0 Rewards

Intech Biopharm Corporation Key Details

NT$107.5m

Revenue

NT$218.5m

Cost of Revenue

-NT$110.9m

Gross Profit

NT$278.1m

Other Expenses

-NT$389.0m

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
-2.39
-103.18%
-361.80%
108.0%
View Full Analysis

About 6461

Founded
2010
Employees
90
CEO
Manish Chawla
WebsiteView website
www.intechbiopharm.com

Intech Biopharm Corporation engages in developing and manufacturing generic drugs to treat respiratory diseases in Taiwan and internationally. It owns iLEF (inhaled low ethanol formulation), a metered dose inhaler platform for treating asthma and COPD; and dry powder inhaler, a product comprises of blisters and capsules. The company offers its products under the SYN006, SYN010, SYN007, Synflutide, Duasma, Synvent, and SYN011 names. Intech Biopharm Corporation was founded in 2010 and is headquartered in Taipei, Taiwan.

Recent 6461 News & Updates

Recent updates

No updates